XTER:HPHA (Germany)
Â
Akt. nach Kapitalherabsetzung
€
2.40
(+0.84%)
Nov 29
Business Description
Heidelberg Pharma AG
NAICS : 325414
SIC : 2836
ISIN : DE000A11QVV0
Share Class Description:
XTER:HPHA: Akt. nach KapitalherabsetzungDescription
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 229.99 | |||||
| Equity-to-Asset | 0.55 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -4.87 | |||||
| Beneish M-Score | 0.46 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -9.3 | |||||
| 3-Year EBITDA Growth Rate | 12 | |||||
| 3-Year EPS without NRI Growth Rate | 10.2 | |||||
| 3-Year FCF Growth Rate | -4.8 | |||||
| 3-Year Book Growth Rate | 36.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -28.35 | |||||
| Future 3-5Y Total Revenue Growth Rate | 9.85 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.56 | |||||
| 9-Day RSI | 56.92 | |||||
| 14-Day RSI | 51.89 | |||||
| 6-1 Month Momentum % | -12.33 | |||||
| 12-1 Month Momentum % | -6.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.01 | |||||
| Quick Ratio | 4.6 | |||||
| Cash Ratio | 4.19 | |||||
| Days Inventory | 2387.58 | |||||
| Days Sales Outstanding | 25.96 | |||||
| Days Payable | 1184.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.5 | |||||
| Shareholder Yield % | 6.31 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 80.41 | |||||
| Operating Margin % | -263.79 | |||||
| Net Margin % | -221.51 | |||||
| FCF Margin % | -357.29 | |||||
| ROE % | -42.09 | |||||
| ROA % | -27.27 | |||||
| ROIC % | -85.83 | |||||
| ROC (Joel Greenblatt) % | -349.11 | |||||
| ROCE % | -34.94 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 11.97 | |||||
| PB Ratio | 2.85 | |||||
| Price-to-Tangible-Book | 4.14 | |||||
| EV-to-EBIT | -4.01 | |||||
| EV-to-Forward-EBIT | -1.64 | |||||
| EV-to-EBITDA | -4.21 | |||||
| EV-to-Forward-EBITDA | -1.64 | |||||
| EV-to-Revenue | 8.91 | |||||
| EV-to-Forward-Revenue | 8.38 | |||||
| EV-to-FCF | -2.23 | |||||
| Price-to-Median-PS-Value | 0.87 | |||||
| Price-to-Net-Current-Asset-Value | 5 | |||||
| Price-to-Net-Cash | 17.14 | |||||
| Earnings Yield (Greenblatt) % | -24.93 | |||||
| FCF Yield % | -27.07 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Heidelberg Pharma AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 8.472 | ||
| EPS (TTM) (€) | -0.41 | ||
| Beta | -0.13 | ||
| Volatility % | 43.16 | ||
| 14-Day RSI | 51.89 | ||
| 14-Day ATR (€) | 0.100669 | ||
| 20-Day SMA (€) | 2.3435 | ||
| 12-1 Month Momentum % | -6.23 | ||
| 52-Week Range (€) | 2.17 - 4.07 | ||
| Shares Outstanding (Mil) | 46.6 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Heidelberg Pharma AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Heidelberg Pharma AG Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Heidelberg Pharma AG Frequently Asked Questions
What is Heidelberg Pharma AG(XTER:HPHA)'s stock price today?
The current price of XTER:HPHA is €2.40. The 52 week high of XTER:HPHA is €4.07 and 52 week low is €2.17.
When is next earnings date of Heidelberg Pharma AG(XTER:HPHA)?
The next earnings date of Heidelberg Pharma AG(XTER:HPHA) is 2025-03-25 Est..
Does Heidelberg Pharma AG(XTER:HPHA) pay dividends? If so, how much?
Heidelberg Pharma AG(XTER:HPHA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers